An international consortium of 56 medical societies has rebranded polycystic ovary syndrome as polyendocrine metabolic ovarian syndrome (PMOS). The change, detailed in a Lancet paper, follows years of surveys involving thousands of patients and clinicians who argued the old label mischaracterized a disorder that touches hormones, metabolism and cardiovascular health. Roughly 10‑13% of women of reproductive age are affected, according to WHO.

Clinicians have long taught PMOS within gynecology curricula, leaving endocrine and metabolic aspects under‑examined. Researchers such as Dr. Melanie Cree reported that NIH grant applications were routinely routed to the reproductive‑health institute, which commands a modest budget, stifling studies on diabetes and heart disease links. The broader label is expected to unlock funding streams from agencies that oversee metabolic research.

Practitioners now advise routine screening for insulin resistance, cholesterol and sleep‑apnea in PMOS patients, moving beyond the common prescription of hormonal contraceptives alone. By framing the disorder as a chronic endocrine condition, pharmaceutical firms may pursue new indications for existing drugs, while insurers could adjust coverage policies to include metabolic testing. The rename instantly expands clinical pathways for millions of women.